Plain-English translation of NCT05934331 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new drug called combined with other cancer treatments to see if it can help people with advanced digestive tract cancer. The cancer being studied has a specific protein marker called CLDN18.2, which helps doctors identify which patients might benefit from this treatment. Researchers want to learn whether this medication combination is safe and effective for people whose cancer has not responded to standard first-line therapies.
Advanced digestive tract cancers are serious and often don't respond well to standard treatments. This study exists to see if the medication can offer a new hope for patients whose cancers have already been treated with initial therapies but continue to grow or cause problems.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication, , in combination with other anti-cancer therapies (either with a drug called or with other approved cancer treatments). You would likely visit the study center regularly for infusions, blood tests, and imaging scans to monitor how you respond to treatment. The study will track how well the treatment works, how safe it is, and what side effects you experience over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
LaNova Medicines Zhejiang Co., Ltd.
Enrollment target
~276 participants
Started
July 2023
Primary completion
July 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alex Yuan
Shanghai East Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.